# Radiomics predicts poorly differentiated hepatocellular carcinoma and uncovers ribosomal-immune dysregulation mechanism

**Authors:** Yiping Gao, Dong Liu, Yifan Miao, Zhiqian Lou, Ziwei Luo, Yonggang Li, Hongfa Cai, Yan Zhu, Shuangqing Chen

PMC · DOI: 10.1016/j.isci.2026.114699 · 2026-01-19

## TL;DR

This study uses radiomics to noninvasively predict liver cancer grades and identifies a link between imaging patterns and tumor biology, including ribosomal and immune system dysregulation.

## Contribution

A novel radiogenomic framework is introduced for noninvasive HCC grading and uncovering ribosomal-immune dysregulation mechanisms.

## Key findings

- A multi-VOI random forest model achieved high accuracy in predicting HCC grades (AUC 0.959 internally, 0.860 externally).
- Radiogenomic analysis revealed associations between imaging features and ribosomal dysregulation and immune exhaustion.
- A prognostic signature derived from radscore independently predicted patient survival in TCGA-HCC data.

## Abstract

Hepatocellular carcinoma (HCC) shows marked spatial heterogeneity, limiting biopsy-based Edmondson-Steiner (ES) grading. We developed a multicenter radiogenomic framework to noninvasively predict ES grade and explore underlying molecular mechanisms. Arterial-phase DCE-MRI from 295 patients and The Cancer Imaging Archive (TCIA) cases were analyzed using three tumor regions (body, edge, and out). An integrated volume-of-interest (VOI) random forest (RF) model was trained with selected features and externally validated. Radiogenomic analysis correlated radscore with TCIA transcriptomic profiles using weighted gene co-expression network analysis (WGCNA). The model achieved high discrimination (area under the curve [AUC] 0.959 internally; 0.860 externally). Radscore-associated modules revealed ribosomal dysregulation and immune exhaustion. A derived prognostic signature stratified and The Cancer Genome Atlas (TCGA) patients into distinct risk groups and independently predicted survival (hazard ratio [HR] 3.95, p < 0.0001; C index 0.643). This integrated radiogenomic approach enables noninvasive ES grading and provides insight into biologically relevant tumor heterogeneity.

•Integrated multi-VOI radiomics enables noninvasive Edmondson-Steiner grading in HCC•An externally validated random forest model achieves robust multicenter performance•Radiogenomic analysis links imaging heterogeneity to ribosomal dysregulation and immunity•A radscore-derived signature independently predicts survival in TCGA-HCC patients

Integrated multi-VOI radiomics enables noninvasive Edmondson-Steiner grading in HCC

An externally validated random forest model achieves robust multicenter performance

Radiogenomic analysis links imaging heterogeneity to ribosomal dysregulation and immunity

A radscore-derived signature independently predicts survival in TCGA-HCC patients

Cancer; molecular interaction; molecular network

## Linked entities

- **Diseases:** hepatocellular carcinoma (MONDO:0007256), HCC (MONDO:0007256)

## Full-text entities

- **Genes:** RPL30 (ribosomal protein L30) [NCBI Gene 6156] {aka L30, eL30}, RPS19 (ribosomal protein S19) [NCBI Gene 6223] {aka DBA, DBA1, LOH19CR1, S19, eS19}, RPS20 (ribosomal protein S20) [NCBI Gene 6224] {aka S20, uS10}, RPL35A (ribosomal protein L35a) [NCBI Gene 6165] {aka DBA5, L35A, eL33}, RPS5 (ribosomal protein S5) [NCBI Gene 6193] {aka S5, uS7}, RPL29 (ribosomal protein L29) [NCBI Gene 6159] {aka HIP, HUMRPL29, L29, RPL29P10, RPL29_3_370, eL29}, RPL18A (ribosomal protein L18a) [NCBI Gene 6142] {aka L18A, eL20}, RPL6 (ribosomal protein L6) [NCBI Gene 6128] {aka L6, SHUJUN-2, TAXREB107, TXREB1, eL6}, RPL18 (ribosomal protein L18) [NCBI Gene 6141] {aka DBA18, L18, eL18}, RPL8 (ribosomal protein L8) [NCBI Gene 6132] {aka L8, uL2}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}
- **Diseases:** TCIA (MESH:D009369), hepatocellular-cholangiocarcinoma (MESH:D018281), tumorigenesis (MESH:D063646), dysregulation (MESH:D021081), metastasis (MESH:D009362), hepatic, renal, or cardiac dysfunction (MESH:D006331), ES grade III/IV (MESH:D005909), HCC tumors (MESH:D006528), necrosis (MESH:D009336), ES (OMIM:605130)
- **Chemicals:** DCE (-), gadolinium (MESH:D005682)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** AUC of 0, L18A, L18

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12925126/full.md

---
Source: https://tomesphere.com/paper/PMC12925126